Group items tagged

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Our acupuncturist resolve various health problem such as drug addictions,nervous disorder,respiratory disorder and allergies by the best acupuncture technique.Sonie Clinic is one of the best heath care clinic performing acupuncture, chiropractic and massage treatment for various problem such as pain relief,infertility.

Our clinic perform best chiropractic and acupuncture treatment to resolve problem such as fertility,postpartum,body pain,migraine headaches & respiratory problem.Sonie Clinic offers prenatal massage, prenatal aupuncture & fertility as well as acupuncture during pregnancy & postpardum recovery.Our specialized pregnancy therapeutic massages infuse relaxation and induce a pain free zone for our pregnant patients. Prenatal massage has long been considered vital to the health of the mother and has

The Neo Orthopaedic Clinic provides best kind of treatments for joint related problems such as ankle, knee, shoulder etc. It is a well known Knee Joint Replacement Clinic in Delhi.

Ankle is a delicate part of body and bears incredible load lots of times. In case you require a Ankle Replacement Clinic in Delhi, then coming to the Neo Orthopaedic Clinic for treatment will be best choice for healthy future.

Olive health & travel clinic ilford, London provide quality medical services in different fields like Private BCG london, Slimming jab, InterVax, Mobile phlebotomy, BCG NHS, Umrah vaccination, Ear irrigation, Hajj vaccination, BCG Injection. We also provide Travel vaccinations and antimalarials, Health Immunisations such as BCG, Shingles, HPV, Meningitis, Hepatitis B etc., Blood tests, Mobile phlebotomy (blood tests at home), Ear wax removal by irrigation method, Weight loss clinic (Saxenda), DNA/Paternity tests, and a range of health checks including STI testing.

Steady Care Medical is a Clinic located in Santa Ana, California. Steady Care Medical specializes in the treatment of mental health, substance, drug and alcoho…

Steady Care Medical is a Clinic located in Santa Ana, California. Steady Care Medical specializes in the treatment of mental health, substance, drug and alcohol abuse.

Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist Professor Mahendra Patel. The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner, prevent the need for hospital admission and so ease the burden on the NHS. The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's Primary Care Clinical Trials Unit. Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK. Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."

Are you looking for a professional Osteo and Physio Massage Clinic in London Bridge? Osteo LDN, we are the leading clinic by delivering quality and value to our clients. Call us now at 020 3301 1210.

Are you looking for a professional Osteo and Physio Massage Clinic in London? Osteo LDN, we are the leading clinic by delivering quality and value to our clients. Call us now at 020 3301 1210.

Are you looking for a professional Osteo and Physio Massage Clinic in London? Osteo LDN, we are the leading clinic by delivering quality and value to our clients. Call us now at 020 3301 1210.

Are you looking for a professional Osteo and Physio Massage Clinic in London? Osteo LDN, we are the leading clinic by delivering quality and value to our clients. Call us now at 020 3301 1210.

Are you looking for a professional Osteo and Physio Massage Clinic in London? Osteo LDN, we are the leading clinic by delivering quality and value to our clients. Call us now at 020 3301 1210.

Are you looking for a professional Osteo and Physio Massage Clinic in London? Osteo LDN, we are the leading clinic by delivering quality and value to our clients. Call us now at 020 3301 1210.

Oxford Cannabinoid Technologies Holdings plc, which specialises in developing cannabis-derived medicines with pain-relieving properties, has successfully administered the first-in-human dose of its lead pharmaceutical drug compound, OCT461201, in its phase 1 clinical trial. The company holds a portfolio of four drug candidates intended for use as licensed pain medications. The drug is a selective cannabinoid receptor type 2 agonist with the potential to treat chemotherapy-induced peripheral neuropathy and irritable bowel syndrome. The UK trial, conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd., is progressing with healthy volunteers, OCTP said in a statement. Using a single ascending dose protocol, the primary objective is to demonstrate OCT461201's safety and tolerability, while providing information on its pharmacokinetic profile, to confirm its value as a potential drug. Results from the trial, funded entirely by OCTP's existing resources, are expected in the third quarter of 2023, the statement added.

British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme. The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment.

he Pharmacy Schools Council (PhSC) has elected Professor Katie Maddock as the organisation's new chair. Prior to becoming head of school at Keele University, Professor Maddock had been MPharm course director and associate dean for education for the Faculty of Medicine and Health Sciences, responsible for developing the clinical teaching at Keele. Before joining Keele University, she taught clinical pharmacy and pharmacy practice at Aston University. Her research interests lie in pharmacy education, particularly the use of technology in teaching, clinical therapeutics, augmented reality simulation and interprofessional education. She was also awarded a principal fellowship of the Higher Education Academy in November 2020. Having worked in hospital pharmacy, Professor Maddock is acutely aware of the pressures that Covid-19 has placed on healthcare, as well as the importance of retaining and building upon the positive changes to patient care and pharmacy practice that were developed in response to the pandemic.

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.

Dr Amanda Doyle has been appointed as NHS England as director of primary and community care. Prior to her new role, Amanda had joined NHS England and NHS Improvement as North West Regional Director on 2 August 2021 and previously she was the Chief Clinical Officer for West Lancashire Clinical Commissioning Group (CCG), Blackpool CCG and Fylde and Wyre CCG. Amanda was also the Integrated Care System Lead for Lancashire and South Cumbria, leading a large health and care transformation programme across the patch. She has been a GP for more than 20 years, practising in a large practice in a deprived area of Blackpool, which, in addition to primary medical services, provides a range of urgent care services for patients across the Fylde Coast. Amanda was the Co-Chair of NHS Clinical Commissioners from 2013 to 2018. She was Senior Responsible Officer for the primary care component of the Long Term Plan and was involved in the leadership of the health inequalities, prevention and personalisation elements.

The fusion of the unique in-depth understanding of medicines by pharmacists together with the competence to prescribe offers will improve access to care and increase capacity in the health system, said the Royal Pharmaceutical Society (RPS) Director for England Ravi Sharma to Parliament at the Health and Social Care Select Committee's inquiry on workforce on Monday (May 23). However, he also stated that a new workforce strategy must support and harness the skills of pharmacist independent prescribers in clinical care with investment in training, both for new and existing workforce; access to supervisors; protected learning and development time; and commissioning of services to make best use of independent prescribers across care settings, supported by appropriate prescribing budgets in community pharmacy. "We're about to see new generation of pharmacists independent prescribers that will make a huge difference to the clinical role of pharmacists to support patient care, but this must be underpinned by protected learning time and a more ambitious approach to commissioning new services to use their skills," Ravi said. He spoke to MPs in Parliament at the Health and Social Care Select Committee's inquiry on workforce, highlighting the vital contribution of pharmacy teams during the pandemic and called for action to support the current and future workforce. Some of the key issues highlighted in the parliament included, the risk of burnout and the need to help boost staff retention; staff wellbeing, including a zero tolerance of abuse from the public; the importance of professional development and protected learning time to enhance patient care and support rewarding careers; the potential of new pharmacist independent prescribers and the need for investment in the current workforce and the need for better workforce data and a pharmacy workforce strategy.

Keith Ridge, who retired from the role of England's chief pharmaceutical officer this month, has written to the NHS regional directors regarding a package to empower community pharmacies to implement clinical services in their integrated care systems. Though details about this letter are not available, Malcolm Harrison, chief executive officer of the Company Chemists' Association, welcomed the move saying: "It is a positive step towards the greater integration of community pharmacy care into the NHS. "It is vital for the NHS that patients can benefit from the clinical care services set out in the Community Pharmacy Contractual Framework." Harrison, however, highlighted that while pharmacies are being pushed to do more, the efforts to introduce new clinical services should be supported with "sustainable funding and material actions to increase workforce numbers in the sector." "We are concerned that without the funding and people in place, the desired volume of necessary services cannot be delivered, no matter how well coordinated."

ECG has launched a new 'simple and straightforward' Patient Group Direction (PGD) service for pharmacists working in primary care, together with a service which offers direct access to an NHS Consultant for medical advice to offer robust safeguarding as and when needed. Taking on more clinical services with the PGDs can feel daunting and a big responsibility for healthcare professionals. ECG's new medical advice service (for anyone purchasing their PGDs) will offer pharmacists the opportunity to call and speak to a clinical member of the ECG team who will triage the calls and support them. If required, the call will be connected to an experienced NHS Consultant to offer immediate medical advice. The service will start with a Monday-Friday 08:30-16:30hrs provision with an option to increase to 24 /7 for those working out of hours. This is inclusive in the PGD pricing offer. ECG has been the market leader in providing vaccination training to pharmacists since 2004, providing robust knowledge and clinical skills to enable pharmacists to develop their private and NHS commissioned vaccination services (such as flu and covid). By developing their close working relationship with all of the multiples, many smaller chains, membership groups and independents over the years, ECG has continued to further consolidate their 'one stop shop' approach to supporting the sector. ECG wants to offer this sector choices in the level of guidance and support that the individual healthcare professionals feel they need to offer safe care to patients.

LloydsPharmacy Clinical Homecare, a leading provider of home healthcare services in the UK, on Monday announced the appointment of Paul Adams as the company's new Chief Executive Officer (CEO). Before assuming his role at LPCH at the end of last year, Adams was leading transformation efforts at DD Group, formerly known as Dental Directory. With a career spanning over two decades, Adams has held influential positions at Diageo, Smith+Nephew, and served as a CEO for various Private Equity companies. He has also co-authored "The Little Black Book of Change." Adams will lead the LPCH's mission to pioneer the delivery of specialist clinical treatment therapies to patients, thereby enhancing patient outcomes within homecare and community settings while improving accessibility.